This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
22 Jan 2015

Mark Copley to Discuss Optimal Testing Methods for DPIs at Inaugural Harro Höfliger Symposium

Mark Copley, Sales Director for Copley Scientific, will discuss optimal in vitro testing methods for dry powder inhalers (DPIs) at the inaugural Harro Höfliger Innovation Days symposium which is being run in co-operation with Capsugel. His invited presentation on 23 February 2015 is part of a 2-day event that will cover all aspects of capsule-based DPI technology. The event takes place at the Hotel Sonne and Harro Höfliger Verpackungsmaschinen GmbH headquarters in Germany.



Mark Copley’s presentation will provide a basic introduction to the dose uniformity and aerodynamic particle size distribution methods required for the testing of orally inhaled products (OIPs), according to the requirements of USP, Ph.Eur., EMA and US FDA, with specific emphasis on DPIs. These tests are used for product development and into QC. DPIs, because of the way they operate, are arguably the most challenging OIP to test. Mr Copley will explain how to achieve robust and reliable test data for this important class of products, whether testing generics or new drug entities. 



During the symposium experts from academia and industry will deliver presentations and workshops on all aspects of capsule- based DPI technology, from powder characterisation and formulation to the devices used and capsule filling technology.

Related News